Affinage

DAB2IP

Disabled homolog 2-interacting protein · UniProt Q5VWQ8

Length
1189 aa
Mass
131.6 kDa
Annotated
2026-06-09
100 papers in source corpus 40 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DAB2IP is a multidomain scaffold and Ras-GTPase-activating protein that functions as a tumor suppressor by restraining mitogenic and survival signaling while licensing apoptotic and checkpoint responses (PMID:11812785, PMID:19903888). Originally cloned as a RasGAP-family protein interacting with DOC-2/DAB2 through a Ras-GAP homology domain, proline repeats, and a leucine zipper (PMID:11812785, PMID:11944990), it directly restrains H-, N-, and wild-type RAS GTP-loading to suppress mitogenic signaling (PMID:33348649, PMID:36939385), an activity supported by stabilizing partners such as RASSF1A (PMID:33348649). As a scaffold it partitions TNF signaling: at the plasma membrane DAB2IP (AIP1) sits in a closed conformation bound to TNFR1, and upon TNF stimulation translocates to the cytoplasm where its PERIOD-like domain engages the TRAF2 RING to enhance ASK1/JNK activation while inhibiting IKK-NF-κB signaling (PMID:15310755), and its proline-rich and PER domains concurrently suppress PI3K-Akt survival signaling (PMID:19903888). Through these and related circuits DAB2IP suppresses epithelial-to-mesenchymal transition and cancer stem-cell properties by limiting nuclear β-catenin/TCF activity, c-kit–PI3K–Akt–mTOR–ZEB1 signaling, and noncanonical WNT/RAC1 signaling (PMID:20080667, PMID:25043300, PMID:32816909, PMID:36536485), and it antagonizes androgen receptor genomic and non-genomic (c-Src) signaling and intratumoral testosterone synthesis (PMID:23604126, PMID:35452821). DAB2IP additionally controls mitotic fidelity and DNA replication: it directly binds PLK1 to sustain kinase activity, BubR1 kinetochore loading, and spindle-assembly-checkpoint integrity (PMID:27568005), is phosphorylated by Cdks to scaffold the PLK1-Mps1-Cdc20 axis and stabilize the mitotic checkpoint complex (PMID:34775484), and in the nucleus promotes HBO1-PLK1-mediated H3K14 acetylation enabling MCM loading and origin firing under ATR/CDK1 control (PMID:41261855). It stabilizes wild-type p53 by competing with GRP75 (PMID:35150809) and inhibits HIF-1α by bridging the E3 ligase STUB1 (PMID:38862467), while being itself inactivated by direct binding of mutant p53 (PMID:25454946, PMID:28667123), epigenetic EZH2-mediated silencing (PMID:22696229, PMID:32816909), and Akt/Fbw7/Skp2/Smurf1-driven proteasomal degradation (PMID:24912918, PMID:25115390, PMID:27036023). A C2-domain missense variant impairing DAB2IP-VEGFR2 interaction links the protein to endothelial VEGF/VEGFR2 signaling and vascular permeability (PMID:38823490).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2002 High

    Established DAB2IP's molecular identity, defining it as a RasGAP-family scaffold that partners with DOC-2/DAB2 to block mitogenic gene expression and prostate cancer growth.

    Evidence Yeast two-hybrid cloning, reciprocal Co-IP, domain characterization and growth assays; promoter mapping and luciferase reporters

    PMID:11812785 PMID:11944990

    Open questions at the time
    • Did not resolve which RAS isoforms are direct GAP substrates
    • Mechanism of epigenetic promoter silencing not defined at the chromatin level
  2. 2003 Medium

    Connected DAB2IP to neuronal signaling by showing it binds the Dab1 PTB domain via an NPxY motif, positioning it downstream of Reelin signaling in the developing brain.

    Evidence Yeast two-hybrid, Co-IP from brain lysates, domain mapping, in situ hybridization

    PMID:12877983

    Open questions at the time
    • Functional consequence of the Dab1 interaction for Ras signaling not tested in vivo
  3. 2004 High

    Revealed the conformational switch underlying DAB2IP's TNF scaffolding: TNF releases it from TNFR1 to form a TRADD/RIP1/TRAF2 complex that drives ASK1 while suppressing NF-κB.

    Evidence Co-IP, subcellular fractionation, deletion-mutant and domain mapping, signaling reporters in endothelial cells

    PMID:15310755

    Open questions at the time
    • Trigger for the conformational opening not defined biochemically
    • Stoichiometry of the multiprotein signaling complex unresolved
  4. 2009 High

    Defined DAB2IP as a dual-function scaffold that suppresses PI3K-Akt while enhancing ASK1 apoptotic signaling, with distinct domains assigned to each arm and validated in a knockout mouse.

    Evidence Domain-deletion mutagenesis, signaling Westerns, DAB2IP knockout mouse, xenograft

    PMID:19903888

    Open questions at the time
    • How the two signaling arms are temporally coordinated not addressed
  5. 2013 High

    Extended DAB2IP's tumor-suppressor reach to EMT, androgen receptor signaling, chemoresistance and cancer stemness, defining multiple downstream transcriptional and kinase circuits it restrains.

    Evidence Cell-line gain/loss-of-function, reporter assays, c-Src kinase assays, domain mutants, KO mouse models, clinical specimens

    PMID:20080667 PMID:23604126 PMID:23838317 PMID:25043300

    Open questions at the time
    • Direct versus indirect nature of several transcriptional effects (β-catenin/TCF, c-kit) not fully separated
    • How a single scaffold engages so many pathways in one cell unresolved
  6. 2014 High

    Identified the post-translational regulatory network that inactivates DAB2IP, including Akt1 phosphorylation, Fbw7/Skp2-mediated degradation, and direct mutant-p53 binding that reroutes TNF signaling toward NF-κB.

    Evidence In vitro kinase assays, Co-IP, ubiquitination/proteasome assays, phospho-degron mutants, STAT3 domain mapping, xenografts

    PMID:24912918 PMID:25115390 PMID:25454946 PMID:26512963

    Open questions at the time
    • Relative contributions of competing E3 ligases in vivo not ranked
    • Whether mutp53 binding is direct or bridged not fully resolved
  7. 2016 High

    Uncovered DAB2IP's mitotic role, showing it directly binds PLK1 to sustain kinase activity, BubR1 kinetochore loading, and spindle-assembly-checkpoint integrity.

    Evidence Co-IP, PLK1 kinase activity assay, BubR1 phosphorylation, kinetochore immunofluorescence, chromosomal segregation and drug-sensitivity assays

    PMID:27568005

    Open questions at the time
    • Whether DAB2IP is a PLK1 substrate or allosteric activator at this stage unclear
    • Nuclear/mitotic localization mechanism not defined
  8. 2017 Medium

    Broadened DAB2IP's GAP repertoire beyond RAS to RAB40C, linking its GAP domain to lipid droplet homeostasis, and added KIF3a binding tying it to primary cilia stability.

    Evidence Co-IP, GAP-defective mutants, CRISPR knockout, lipid droplet imaging; mass-spec interactome and PH-domain mapping for KIF3a

    PMID:29156729 PMID:33341566

    Open questions at the time
    • Direct GAP activity on RAB40C not measured biochemically
    • Cilia phenotype mechanism beyond KIF3a binding unresolved
  9. 2021 High

    Defined a Cdk-phosphorylation-dependent mode in which DAB2IP scaffolds the PLK1-Mps1-Cdc20 axis to stabilize the mitotic checkpoint complex and prevent premature APC/C activation.

    Evidence Cdk phospho-site mutagenesis, multiple Co-IPs, Cdc20 ubiquitylation assay, SAC and genomic-instability readouts

    PMID:34775484

    Open questions at the time
    • Which Cdk(s) phosphorylate DAB2IP in vivo not pinpointed
    • Structural basis of MCC stabilization unknown
  10. 2022 High

    Established DAB2IP as a regulator of p53 stability and tumor metabolism, competing with GRP75 to protect wild-type p53 and bridging STUB1 to degrade HIF-1α.

    Evidence Mass-spec complex identification, competitive Co-IP, ubiquitination assays, domain mapping, glucose/ATP/lactate metabolic readouts, in vivo

    PMID:35150809 PMID:38862467

    Open questions at the time
    • Whether p53 stabilization and HIF-1α degradation occur in the same cellular context not tested
    • Domain assignments differ (Ras-GAP vs PER) across substrates without unifying model
  11. 2023 Medium

    Linked DAB2IP to mechanotransduction and the tumor microenvironment, showing confluency-dependent suppression of YAP/TAZ and that its loss recruits protumorigenic macrophages via inflammatory signaling.

    Evidence Bidirectional perturbation with YAP/TAZ localization, atomic force microscopy; RAS-GTP assays, cytokine profiling, in vivo macrophage depletion and JAK/TBK1 inhibition

    PMID:36939385 PMID:37444489

    Open questions at the time
    • Molecular link between DAB2IP and the YAP/TAZ machinery not defined
    • Direct versus secondary nature of inflammatory mediator induction unresolved
  12. 2025 High

    Defined a nuclear, replication-licensing function in which ATR/CDK1-phosphorylated DAB2IP scaffolds HBO1-PLK1 to drive H3K14 acetylation, MCM loading and origin firing.

    Evidence Nuclear fractionation, Co-IPs, PLK1 kinase assay, ChIP for H3K14Ac at origins, MCM loading assay, phospho-site mutagenesis, genomic-instability readouts

    PMID:41261855

    Open questions at the time
    • Mechanism of DAB2IP nuclear import not established
    • How nuclear replication role coordinates with cytoplasmic GAP/scaffold functions unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single multidomain scaffold dynamically partitions among plasma membrane, cytoplasm, and nucleus to selectively engage RAS-GAP, TNF/ASK1, checkpoint, and replication functions remains unresolved.
  • No integrated model of spatial/temporal regulation across compartments
  • No structural model of full-length DAB2IP with partners
  • Direct GAP activity quantified for only a subset of GTPases

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 5 GO:0098772 molecular function regulator activity 4 GO:0140096 catalytic activity, acting on a protein 3
Localization
GO:0005829 cytosol 3 GO:0005886 plasma membrane 2 GO:0005634 nucleus 1 GO:0005811 lipid droplet 1 GO:0005929 cilium 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1640170 Cell Cycle 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-1643685 Disease 2 R-HSA-69306 DNA Replication 1
Partners
CDC20DAB2GRP75HBO1PLK1RASSF1ASTUB1TRAF2
Complex memberships
DAB2IP-p53-GRP75 complexHBO1-PLK1 replication-licensing complexPLK1-Mps1-Cdc20 mitotic checkpoint moduleTNFR1-TRADD-RIP1-TRAF2 signaling complex

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 DAB2IP (then called DIP1/2) was cloned as a novel GTPase-activating protein (GAP) that interacts with the N-terminal domain of DOC-2/DAB2. It contains a Ras-GAP homology domain, 10 proline repeats, and a leucine zipper. Interaction between DOC-2/DAB2 and DIP1/2 is detected in normal brain and prostate tissues. The complex blocks mitogen-induced gene expression and inhibits prostate cancer growth. Yeast two-hybrid cloning, co-immunoprecipitation, structural domain characterization, functional growth assays The Journal of Biological Chemistry High 11812785
2002 Human DAB2IP is a novel member of the Ras-GTPase-activating protein family that directly interacts with DAB2. The gene is located at 9q33.1-q33.3, spans ~96 kb with 15 exons, and its promoter lacks a TATA box. Transcriptional downregulation via epigenetic mechanisms (reduced promoter activity) is responsible for loss of DAB2IP expression in prostate cancer cells. Molecular cloning, promoter mapping and luciferase reporter assay, RT-PCR expression analysis Genomics Medium 11944990
2003 Mouse Dab2IP interacts with the intracellular adapter protein Disabled-1 (Dab1) in brain lysates; the interaction is mediated by the Dab1-PTB domain and an NPxY motif in Dab2IP. This positions Dab2IP as a potential downstream effector in the Reelin signaling pathway that influences Ras signaling during brain development. Yeast two-hybrid screen, co-immunoprecipitation from brain lysates, domain mapping, Northern blot, in situ hybridization, immunohistochemistry Brain Research. Molecular Brain Research Medium 12877983
2004 DAB2IP (AIP1) is localized on the plasma membrane of resting endothelial cells in a complex with TNFR1. TNF binding induces AIP1 release from TNFR1, cytoplasmic translocation, and formation of a signaling complex with TRADD, RIP1, TRAF2, and AIP1. A proline-rich region (aa 796–807) maintains AIP1 in a closed conformation associated with TNFR1; deletion of this region causes constitutive binding to TRAF2 and ASK1. A PERIOD-like domain (aa 591–719) binds the RING finger of TRAF2 and enhances TRAF2-induced ASK1 activation, while simultaneously inhibiting IKK-NF-κB signaling. Co-immunoprecipitation, subcellular fractionation, deletion mutant analysis, domain mapping, signaling reporter assays The Journal of Biological Chemistry High 15310755
2009 DAB2IP functions as a scaffold protein that simultaneously suppresses the PI3K-Akt survival pathway and enhances ASK1 activation leading to apoptosis. Structural-functional analyses indicate that the proline-rich (PR) and PERIOD-like (PER) domains regulate PI3K-Akt activity, while the C2 domain is critical for ASK1 activity. Loss of DAB2IP in mice results in glandular epithelial hyperplasia and apoptotic defects. Gain-of-function and loss-of-function experiments, domain deletion mutagenesis, Western blot signaling analysis, DAB2IP knockout mouse model, in vivo xenograft Proceedings of the National Academy of Sciences of the United States of America High 19903888
2010 Loss of DAB2IP initiates epithelial-to-mesenchymal transition (EMT) characterized by E-cadherin repression and vimentin upregulation in prostate epithelial and carcinoma cells. DAB2IP functions as a scaffold protein modulating EMT by regulating nuclear β-catenin/TCF transcriptional activity. Restoration of DAB2IP in metastatic PCa cells reversed EMT; knockdown in a xenograft model led to lymph node and distant organ metastases. Knockdown/overexpression in cell lines, DAB2IP knockout mouse model, human prostate xenograft-mouse model, reporter assays, clinical specimen IHC Proceedings of the National Academy of Sciences of the United States of America High 20080667
2012 DAB2IP is epigenetically silenced in medulloblastoma by EZH2-induced trimethylation of its promoter (H3K27me3). Ectopic DAB2IP expression enhances stress-induced apoptosis in medulloblastoma cells, and reduced DAB2IP confers resistance to irradiation-induced cell death. Gene expression meta-analysis, chromatin immunoprecipitation (EZH2/H3K27me3), ectopic expression functional assays, irradiation survival assays Clinical Cancer Research Medium 22696229
2012 DAB2IP is required for proper neuronal migration in the embryonic mouse neocortex. Knockdown disrupts the transition from multipolar to bipolar neuronal morphology in the intermediate zone and impairs neurite development, associated with reduced expression of neuronal microtubule-associated proteins (MAPs). Both PH and GRD (GAP-related) domains are required for neuronal migration. In utero electroporation (shRNA knockdown and overexpression), immunohistochemistry, domain deletion in vivo structure-function analysis, ex vivo neuronal culture PLoS ONE High 23056358
2012 DAB2IP regulates autophagy in prostate cancer cells. Restoring DAB2IP expression decreases autophagy-associated proteins (LC3B, Beclin-1) and reduces phosphorylation of S6K and mTOR, shifting cells toward apoptosis in response to combined radiation and DNA-PKcs inhibition. DAB2IP knockdown/restoration in cell lines, Western blot for autophagy markers and mTOR signaling, apoptosis assays, colony formation, in vivo xenograft Neoplasia Medium 23308052
2013 DAB2IP inhibits androgen receptor (AR) signaling through two distinct mechanisms: (1) suppressing AR nuclear translocation/phosphorylation in the genomic pathway and (2) inactivating c-Src via a unique functional domain in the non-genomic pathway. DAB2IP also inhibits constitutively active AR splice variants. In DAB2IP-/- mice, prostate epithelia show hyperplasia with more active AR. Cell line gain/loss of function, AR nuclear translocation assays, c-Src kinase assays, domain-specific mutants, DAB2IP knockout mouse model, tissue microarray Oncogene High 23604126
2013 DAB2IP blocks cross-talk between Wnt/β-catenin and IGF-I signaling, suppressing Egr-1 expression which in turn controls Clusterin (an antiapoptotic factor). Loss of DAB2IP in chemoresistant prostate cancer cells leads to elevated Egr-1 and Clusterin via this pathway, conferring resistance to docetaxel and other chemotherapeutic drugs. Knockdown/overexpression in cell lines, luciferase reporter assay for Egr-1/Clusterin regulation, rescue experiments (Clusterin shRNA/OGX-011), Western blot signaling, DAB2IP KO mouse model, tissue microarray Clinical Cancer Research High 23838317
2013 Dab2IP deficiency in mouse cerebellum produces a delay in Purkinje cell dendrite development, a decrease in parallel fiber synaptic marker VGluT1, and an increase in climbing fiber synaptic marker VGluT2, demonstrating a role for Dab2IP in dendrite development and synapse number regulation. Retrovirus gene trap Dab2IP knockdown mouse model, immunohistochemistry for synaptic markers, morphological analysis of Purkinje cell dendrites PLoS ONE Medium 23326475
2014 Mutant p53 (mutp53) binds and inhibits DAB2IP in the cytoplasm, thereby fueling NF-κB activation and dampening ASK1/JNK activation in response to TNFα. This leads to increased invasiveness of cancer cells responding to inflammatory cytokines. Interfering with the mutp53-DAB2IP interaction reduced cancer cell aggressiveness in xenografts. Co-immunoprecipitation (mutp53-DAB2IP interaction), cytoplasmic fractionation, NF-κB and ASK1/JNK signaling assays, xenograft mouse model, interference with interaction Molecular Cell High 25454946
2014 DAB2IP suppresses cancer stem cell (CSC) properties by (1) suppressing c-kit (CD117) gene expression through interaction with a silencer element in the c-kit gene, and (2) inhibiting c-kit–PI3K–Akt–mTOR signaling that increases c-Myc to activate ZEB1 gene expression. Loss of DAB2IP elevates ZEB1 and CD117, increasing CSC phenotypes. Gain/loss-of-function in cell lines, promoter-silencer reporter assay, signaling pathway analysis (Western blot), DAB2IP KO mouse model, clinical specimen correlation Oncogene High 25043300
2014 Akt1 phosphorylates DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Additionally, DAB2IP is degraded through the ubiquitin-proteasome pathway by SCF(Fbw7), which recognizes two Fbw7 phospho-degron motifs in DAB2IP regulated by the kinase CK1δ. In vitro kinase assay (Akt1 phosphorylation of DAB2IP), co-immunoprecipitation (DAB2IP-H-Ras/TRAF2), proteasome inhibitor experiments, phospho-degron mutant analysis, CK1δ kinase assays Oncotarget Medium 24912918
2014 DAB2IP interacts with and suppresses STAT3 via its proline-rich (PR) domain, inhibiting STAT3 phosphorylation, transactivation, and downstream survivin expression. Loss of DAB2IP stabilizes mitochondrial transmembrane potential and prevents cytochrome c/Omi/Smac release, conferring resistance to androgen deprivation-induced apoptosis. Co-immunoprecipitation (DAB2IP-STAT3), domain mapping (PR domain), Western blot for apoptotic mediators, mitochondrial membrane potential assay, DAB2IP KO mouse model, luciferase reporter Cell Death & Disease High 26512963
2014 Skp2 (E3 ubiquitin ligase) mediates proteasome-dependent degradation of DAB2IP, with the ubiquitination site located in the N-terminal domain. Reciprocally, DAB2IP suppresses Skp2 protein expression through Akt signaling, forming a homeostatic feedback loop. Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, domain mapping (N-terminal), Western blot with Akt pathway inhibitors, tissue microarray IHC Oncotarget Medium 25115390
2015 DAB2IP regulates neuronal positioning in the developing cortex by modulating Rap1 and integrin signaling. Dab2IP knockdown results in elevated activated Rap1 and integrin levels in the developing cortex, linking Dab2IP to multipolar-to-bipolar transition of migrating neurons via these signaling intermediates. Dab2IP knockdown mouse model (retroviral gene trap), BrdU birth dating, layer-specific marker immunohistochemistry, Rap1 and integrin activation assays Developmental Neuroscience Medium 25721469
2016 Smurf1 (E3 ubiquitin ligase) negatively regulates DAB2IP through ubiquitin-mediated degradation. Smurf1-mediated cell proliferation and migration are largely dependent on DAB2IP as a key effector. Akt1 and Akt2 phosphorylate Smurf1, increasing Smurf1 abundance and further reducing DAB2IP levels. Co-immunoprecipitation, ubiquitination assays, knockdown rescue experiments, Akt phosphorylation assays, cell proliferation and migration assays Oncotarget Medium 27036023
2016 DAB2IP loss impairs kinetochore-microtubule (KT-MT) attachment, compromises the spindle assembly checkpoint (SAC), and causes aberrant chromosomal segregation. Mechanistically, DAB2IP directly interacts with Plk1 and its loss inhibits Plk1 kinase activity, impairing Plk1-mediated BubR1 phosphorylation and reducing BubR1 localization at kinetochores during mitosis. DAB2IP restoration enhances sensitivity to microtubule-stabilizing drugs and a Plk1 inhibitor. Co-immunoprecipitation (DAB2IP-Plk1), kinase activity assay, BubR1 phosphorylation assay, kinetochore localization by immunofluorescence, chromosomal segregation analysis, drug sensitivity assays Nucleic Acids Research High 27568005
2016 DAB2IP suppresses PROX1 transcription in prostate cancer cells. In DAB2IP-deficient cells, PROX1 overexpression stabilizes HIF1α protein by inhibiting the ubiquitin-proteasome pathway, leading to EMT (E-cadherin repression, vimentin upregulation, MMP induction) and enhanced cell migration. Cell line gain/loss-of-function, promoter reporter assays for PROX1, HIF1α ubiquitination and stability assays, Western blot, migration assay, DAB2IP KO mouse model Cellular Signalling Medium 27476001
2016 Loss of DAB2IP in renal cell carcinoma activates ERK/RSK1 and PI3K/mTOR pathways, synergistically inducing HIF-2α expression. Elevated HIF-2α suppresses p21/WAF1, conferring resistance to mTOR inhibitors. Combined targeting of both pathways results in synergistic tumor inhibition. DAB2IP knockdown/overexpression in RCC cell lines, Western blot pathway analysis, HIF-2α knockdown rescue, drug sensitivity assays, in vivo xenograft Oncogene Medium 26876207
2017 Mutant p53 (mutp53) augments insulin-induced AKT1 activation by binding and inhibiting DAB2IP in the cytoplasm, providing a specific gain-of-function for mutant p53 in response to insulin stimulation and increasing cancer cell proliferation and invasiveness. Co-immunoprecipitation (mutp53-DAB2IP in cytoplasmic fractions), AKT1 phosphorylation assays, gain/loss-of-function with cell proliferation and invasion readouts Proceedings of the National Academy of Sciences of the United States of America Medium 28667123
2017 DAB2IP acts as a GAP toward RAB40C GTPase, binding RAB40C mainly via its GAP domain to regulate lipid droplet (LD) homeostasis. Overexpression of DAB2IP or its GAP-defective mutant, and siRNA depletion of DAB2IP, confirm that DAB2IP negatively regulates RAB40C-mediated LD accumulation. Co-immunoprecipitation (DAB2IP-RAB40C), CRISPR-Cas9 RAB40C knockout, GAP-defective mutant overexpression, siRNA depletion, lipid droplet quantification by imaging Oncotarget Medium 29156729
2017 Down-regulation of DAB2IP increases hnRNPK protein levels through the MAPK/ERK signaling pathway, causing translocation of hnRNPK into the nucleus where it enhances MMP2 transcription, thereby promoting invasion and metastasis of colorectal cancer cells. 2D-DIGE proteomics to identify hnRNPK, cDNA microarray to identify MMP2, DAB2IP knockdown/overexpression, nuclear/cytoplasmic fractionation, MMP2 promoter reporter assay, invasion assays International Journal of Cancer Medium 28335083
2018 miR-149-3p is a direct post-transcriptional negative regulator of DAB2IP. Downregulation of DAB2IP by miR-149-3p enhances cancer cell motility and invasiveness, activates NF-κB signaling, promotes expression of pro-inflammatory and pro-angiogenic factors. Notably, miR-149-3p secreted by prostate cancer cells induces DAB2IP downregulation in recipient vascular endothelial cells, stimulating their proliferation and motility. High-throughput miRNA mimic screen, luciferase reporter assay for direct targeting, NF-κB signaling assays, endothelial cell transfer/co-culture experiments, tumor growth assays with endogenous miR-149-3p inhibition Cell Death and Differentiation Medium 29568059
2020 In ovarian cancer stem cells (OCSCs), DAB2IP is silenced by EZH2-mediated H3K27 trimethylation of the DAB2IP promoter. CRISPR/Cas9 deletion of DAB2IP upregulates stemness genes and converts non-CSC to CSC. DAB2IP suppresses the CSC phenotype by inhibiting WNT5B expression, which reduces noncanonical WNT signaling via C-JUN activation downstream of RAC1. CRISPR/Cas9 deletion, ChIP for H3K27me3 at DAB2IP promoter, transcriptomic analysis, reverse phase protein array, RAC1 inhibition experiments, in vivo tumor growth assays Cancer Research High 32816909
2020 RASSF1A binds to DAB2IP and upregulates DAB2IP protein levels in NSCLC cells. Suppression of RASSF1A leads to downregulation of DAB2IP and enhanced GTP loading onto RAS (increased RAS activation), thereby increasing RAS mitogenic signaling in both mutant- and wildtype-RAS cells. Co-immunoprecipitation (RASSF1A-DAB2IP), shRNA knockdown and stable overexpression, Ras-GTP pull-down assay, in vitro and in vivo growth assays Cancers Medium 33348649
2020 DAB2IP physically interacts with KIF3a (kinesin-2 family member) through its PH domain, and this interaction is important for primary cilia stability. Loss of DAB2IP in normal kidney epithelial cells significantly impairs primary cilia formation. Mass spectrometry identification of DAB2IP-interacting proteins (KIF3a), co-immunoprecipitation, domain mapping (PH domain), immunofluorescence for primary cilia Neoplasia Medium 33341566
2021 DAB2IP is phosphorylated by Cdks during mitosis, mediating its interaction with PLK1 and activation of the PLK1-Mps1 pathway. DAB2IP acts as a scaffold to facilitate PLK1-Mps1 targeting of Cdc20. DAB2IP interacts with Cdc20 in a phosphorylation-independent manner; however, DAB2IP phosphorylation inhibits Cdc20 ubiquitylation during SAC, blocking premature APC/C-MCC release. Loss of Cdk-mediated DAB2IP phosphorylation destabilizes the mitotic checkpoint complex (MCC), impairs SAC, and causes chromosomal instability. Phosphorylation site identification and mutagenesis (Cdk sites), co-immunoprecipitation (DAB2IP-PLK1, DAB2IP-Cdc20, PLK1-Mps1), Cdc20 ubiquitylation assay, SAC and chromosomal segregation assays, anaphase bridge/53BP1 body quantification Oncogene High 34775484
2022 DAB2IP interacts with the chaperone GRP75 via its Ras-GAP domain, competitively blocking GRP75-driven ubiquitination and proteasomal degradation of wild-type p53. This DAB2IP-GRP75 interaction stabilizes p53 and mediates tumor-suppressive effects in colon cancer cells. Mass spectrometry (identification of DAB2IP-p53-GRP75 complex), co-immunoprecipitation, competitive binding assay, ubiquitination assay, domain-deletion mutants (Ras-GAP domain required), in vivo tumor experiments Cancer Letters High 35150809
2022 DAB2IP inhibits intratumoral testosterone synthesis in castration-resistant prostate cancer by suppressing AKR1C3 promoter activity and the conversion of DHEA to testosterone through the PI3K/AKT/mTOR/ETS1 signaling pathway, thereby reducing AR re-activation under androgen-depleted conditions. DAB2IP knockdown/overexpression, AKR1C3 promoter luciferase reporter assay, testosterone synthesis measurement, signaling pathway inhibition, in vivo castration model with DAB2IP-/- mice and DHEA supplementation Cellular Signalling Medium 35452821
2022 DAB2IP downregulates HSP90AA1 expression through the HSP90AA1/SRP9/ASK1/JNK signaling axis to promote apoptosis in colorectal cancer cells. Mechanistic studies confirmed the DAB2IP-HSP90AA1 regulatory connection through bioinformatic prediction plus in vitro validation. Bioinformatic pathway analysis, in vitro knockdown/overexpression, apoptosis flow cytometry, Western blot for ASK1/JNK activation, in vivo xenograft BMC Cancer Low 35590292
2022 DAB2IP inhibits β-catenin nuclear transport by competitively interacting with RAC1, thereby reducing β-catenin accumulation in the cell nucleus and attenuating cancer stem cell properties and chemoresistance in triple-negative breast cancer. Co-immunoprecipitation (DAB2IP-RAC1 competitive interaction), nuclear/cytoplasmic fractionation of β-catenin, DAB2IP knockdown/overexpression, in vivo xenograft experiments Clinical and Translational Medicine Medium 36536485
2023 DAB2IP suppresses invadopodia formation and breast cancer metastasis by destabilizing anaplastic lymphoma kinase (ALK) through antagonizing the interaction between the deubiquitinase USP10 and ALK, leading to decreased ALK protein abundance, reduced Cortactin tyrosine phosphorylation, and prevention of invadopodia formation. Co-immunoprecipitation (DAB2IP-USP10-ALK competitive binding), Cortactin phosphorylation assay, invadopodia formation assay, in vivo metastasis model, ALK protein stability assays iScience Medium 37664607
2023 DAB2IP expression is regulated by cell confluency (cell contact). DAB2IP depletion in confluent cells alters cell morphology (reduced cell packing, increased stiffness), favors YAP/TAZ nuclear localization and transcriptional activity, while ectopic DAB2IP expression in subconfluent cells increases YAP/TAZ cytoplasmic retention. DAB2IP knockdown and overexpression, YAP/TAZ nuclear/cytoplasmic localization by immunofluorescence, atomic force microscopy for cell stiffness, confluency-dependent expression analysis Cancers Medium 37444489
2023 DAB2IP is a bifunctional tumor suppressor in KRAS-mutant colorectal cancer: (1) it restrains wild-type H-RAS and N-RAS (required for robust RAS effector pathway activation even in KRAS-mutant tumors), and (2) its loss triggers production of inflammatory mediators and recruitment of protumorigenic macrophages in vivo. Tumor growth was suppressed by macrophage depletion or JAK/TBK1 inhibition in DAB2IP-depleted tumors. DAB2IP genetic loss in colorectal cancer models, Ras-GTP activation assay (H-/N-Ras), cytokine/inflammatory mediator profiling, macrophage depletion in vivo, JAK/TBK1 inhibitor treatment, histological analysis of tumor microenvironment Cancer Research Medium 36939385
2024 A DAB2IP missense variant (p.D239N) in the C2 domain impairs its interaction with VEGFR2, altering the subcellular localization of VEGFR2: wild-type DAB2IP colocalizes with VEGFR2 intracellularly, while the D239N mutant retains VEGFR2 at the cell membrane. This implicates DAB2IP in regulating endothelial VEGF/VEGFR2 signaling and vascular permeability. Whole exome sequencing, protein structure modeling, subcellular localization assay (transfection + immunofluorescence colocalization of DAB2IP variant and VEGFR2), co-localization quantification The Journal of Allergy and Clinical Immunology Medium 38823490
2024 DAB2IP inhibits glucose uptake under hypoxia by interacting with the E3 ubiquitin ligase STUB1 via its PER domain, facilitating STUB1-mediated ubiquitylation and degradation of HIF-1α. Deletion of the PER domain abolishes DAB2IP-mediated inhibition of glucose uptake, ATP production, and lactic acid production. Co-immunoprecipitation (DAB2IP-STUB1-HIF-1α), domain deletion mutagenesis (PER domain), HIF-1α ubiquitylation assay, glucose uptake assay, metabolic assays (ATP, lactate), in vitro and in vivo experiments Oncogenesis High 38862467
2025 Nuclear DAB2IP localizes to the nucleus, where it interacts with the histone acetyltransferase HBO1 and enhances the HBO1-PLK1 interaction. DAB2IP facilitates PLK1-mediated phosphorylation of HBO1, which promotes HBO1-directed H3K14 acetylation, enabling MCM complex loading onto chromatin and supporting DNA replication origin firing. ATR regulates CDK1-mediated phosphorylation of DAB2IP, which is required for HBO1-PLK1 complex formation and activation. Loss of this phosphorylation increases genomic instability (anaphase bridges, 53BP1 nuclear bodies). Nuclear fractionation, co-immunoprecipitation (DAB2IP-HBO1, HBO1-PLK1), PLK1 kinase assay for HBO1 phosphorylation, ChIP for H3K14Ac at replication origins, MCM loading assay, CDK1 phosphorylation site mutagenesis, genomic instability assays (anaphase bridge/53BP1 quantification) Nucleic Acids Research High 41261855

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America 203 20080667
2019 CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell death & disease 195 31776329
1977 Gene mapping in Mus musculus by interspecific cell hybridization: assignment of the genes for tripeptidase-1 to chromosome 10, dipeptidase-2 to chromosome 18, acid phosphatase-1 to chromosome 12, and adenylate kinase-1 to chromosome 2. Cytogenetics and cell genetics 172 198184
2009 DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proceedings of the National Academy of Sciences of the United States of America 166 19903888
2014 Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Molecular cell 145 25454946
2002 The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. The Journal of biological chemistry 128 11812785
2004 AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. The Journal of biological chemistry 103 15310755
2012 EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Clinical cancer research : an official journal of the American Association for Cancer Research 64 22696229
2002 Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 64 11944990
2013 The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 63 23838317
2016 DAB2IP in cancer. Oncotarget 60 26658103
2016 Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer. Cell death and differentiation 59 27858941
2020 MicroRNA-146b-5p overexpression attenuates premature ovarian failure in mice by inhibiting the Dab2ip/Ask1/p38-Mapk pathway and γH2A.X phosphorylation. Cell proliferation 58 33166004
2014 DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene 58 25043300
2018 Circ008913, via miR-889 regulation of DAB2IP/ZEB1, is involved in the arsenite-induced acquisition of CSC-like properties by human keratinocytes in carcinogenesis. Metallomics : integrated biometal science 55 30167605
2020 EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells. Cancer research 53 32816909
2012 DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. Neoplasia (New York, N.Y.) 53 23308052
2015 The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. International journal of radiation biology 49 25585815
2014 Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer science 48 24684735
2015 microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncology letters 46 26622795
2017 Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proceedings of the National Academy of Sciences of the United States of America 45 28667123
2013 The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 43 23604126
1979 Genetics, ontogeny, and testosterone inducibility of aldehyde oxidase isozymes in the mouse: evidence for two genetic loci (Aox-I and Aox-2) closely linked on chromosome 1. Biochemical genetics 43 518535
2022 DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. BMC cancer 41 35590292
2015 miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS letters 41 25841337
2024 DAB2IP associates with hereditary angioedema: Insights into the role of VEGF signaling in HAE pathophysiology. The Journal of allergy and clinical immunology 40 38823490
2014 The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget 38 25115390
2019 Soft fibrin matrix downregulates DAB2IP to promote Nanog-dependent growth of colon tumor-repopulating cells. Cell death & disease 37 30770783
2018 Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell death and differentiation 37 29568059
2017 Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2. International journal of cancer 37 28335083
2016 miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Oncology reports 36 27430302
2018 Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals. Experimental & molecular medicine 34 30459405
2016 Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene 34 26876207
2015 The positive feedback between Snail and DAB2IP regulates EMT, invasion and metastasis in colorectal cancer. Oncotarget 33 26336990
2014 Negative regulation of DAB2IP by Akt and SCFFbw7 pathways. Oncotarget 32 24912918
2015 DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Cellular signalling 31 26410305
2019 miR-92b promotes gastric cancer growth by activating the DAB2IP-mediated PI3K/AKT signalling pathway. Cell proliferation 30 31713929
2016 Smurf1 regulation of DAB2IP controls cell proliferation and migration. Oncotarget 29 27036023
2017 miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression. International journal of oncology 28 28440444
2010 Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. International journal of radiation oncology, biology, physics 27 20970033
2019 miR-182 contributes to cell proliferation, invasion and tumor growth in colorectal cancer by targeting DAB2IP. The international journal of biochemistry & cell biology 26 30974224
2015 DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis. Cell death & disease 25 26512963
2003 Interaction of Disabled-1 and the GTPase activating protein Dab2IP in mouse brain. Brain research. Molecular brain research 25 12877983
2011 Association of a sequence variant in DAB2IP with coronary heart disease. European heart journal 24 21444365
2022 DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation. Biochimica et biophysica acta. Molecular basis of disease 23 35063646
2022 DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. Cell death & disease 23 35562342
2016 Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget 23 27129174
2022 DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer. Cancer letters 22 35150809
2015 Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals. Oncotarget 22 26587829
2013 Dab2IP GTPase activating protein regulates dendrite development and synapse number in cerebellum. PloS one 22 23326475
2012 Dab2ip regulates neuronal migration and neurite outgrowth in the developing neocortex. PloS one 22 23056358
2017 BMAL1 facilitates trophoblast migration and invasion via SP1-DNMT1/DAB2IP pathway in recurrent spontaneous abortion. Oncotarget 21 29163762
2016 DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cellular signalling 21 27476001
2016 Tumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments. Nucleic acids research 21 27568005
2011 A common genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of lung cancer in Chinese males. PloS one 21 22046421
2019 MicroRNA-889 promotes cell proliferation in colorectal cancer by targeting DAB2IP. European review for medical and pharmacological sciences 19 31081086
2017 The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget 19 28978010
2019 Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients. Scientific reports 18 31666665
2018 DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway. Gastroenterology research and practice 18 29743885
2019 Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop. Journal of cellular biochemistry 17 30672020
2018 MiR-1266 promotes cell proliferation, migration and invasion in cervical cancer by targeting DAB2IP. Biochimica et biophysica acta. Molecular basis of disease 17 30261286
2021 Mitotic phosphorylation of tumor suppressor DAB2IP maintains spindle assembly checkpoint and chromosomal stability through activating PLK1-Mps1 signal pathway and stabilizing mitotic checkpoint complex. Oncogene 16 34775484
2022 DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clinical and translational medicine 15 36536485
2017 ATM mediates DAB2IP-deficient bladder cancer cell resistance to ionizing radiation through the p38MAPK and NF-κB signaling pathway. Molecular medicine reports 14 28586028
2013 Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS. Hepatobiliary & pancreatic diseases international : HBPD INT 13 23558076
2023 DAB2IP-knocking down resulted in radio-resistance of breast cancer cells is associated with increased hypoxia and vasculogenic mimicry formation. International journal of radiation biology 12 36947637
2020 Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells. Technology in cancer research & treatment 12 32336215
2006 Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA and cell biology 12 16629596
2024 DAB2IP inhibits glucose uptake by modulating HIF-1α ubiquitination under hypoxia in breast cancer. Oncogenesis 11 38862467
2017 A RasGAP, DAB2IP, regulates lipid droplet homeostasis by serving as GAP toward RAB40C. Oncotarget 11 29156729
2013 Downregulation of DAB2IP promotes mesenchymal-to-neuroepithelial transition and neuronal differentiation of human mesenchymal stem cells. PloS one 11 24073285
2023 DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer. iScience 10 37664607
2015 Dab2IP Regulates Neuronal Positioning, Rap1 Activity and Integrin Signaling in the Developing Cortex. Developmental neuroscience 10 25721469
2023 DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer research 9 36939385
2022 DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling. Cellular signalling 9 35452821
2021 DAB2IP decreases cell growth and migration and increases sensitivity to chemotherapeutic drugs in colorectal cancer. Annals of translational medicine 9 34532454
2020 Bone marrow stromal cells-derived exosomes target DAB2IP to induce microglial cell autophagy, a new strategy for neural stem cell transplantation in brain injury. Experimental and therapeutic medicine 9 32765770
2018 MicroRNA-556-3p promotes the progression of esophageal cancer via targeting DAB2IP. European review for medical and pharmacological sciences 9 30402845
2021 Loss of DAB2IP Contributes to Cell Proliferation and Cisplatin Resistance in Gastric Cancer. OncoTargets and therapy 8 33603402
2015 Expression of DAB2IP in human trophoblast and its role in trophoblast invasion. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 8 25604087
2024 Dihydroartemisinin suppresses the tumorigenesis of esophageal carcinoma by elevating DAB2IP expression in a NFIC-dependent manner. Naunyn-Schmiedeberg's archives of pharmacology 7 38789636
2024 An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications. Cell death and differentiation 7 38902547
2022 Cypermethrin inhibits proliferation of Sertoli cells through AR involving DAB2IP/PI3K/AKT signaling pathway in vitro. Toxicology research 7 36051661
2020 DAB2IP modulates primary cilia formation associated with renal tumorigenesis. Neoplasia (New York, N.Y.) 7 33341566
2020 The RASSF1A Tumor Suppressor Binds the RasGAP DAB2IP and Modulates RAS Activation in Lung Cancer. Cancers 7 33348649
2019 DAB2IP Expression in Abdominal Aortic Aneurysm: EZH2 and mir-363-3p as Potential Mediators. In vivo (Athens, Greece) 7 31028191
2015 Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. Cancer medicine 7 26471467
2016 Upregulating DAB2IP expression via EGR-1 inhibition, a new approach for overcoming fractionated-irradiation-induced cross-tolerance to ionizing radiation and mitomycin C in tumor cells. International journal of radiation biology 6 27834104
2012 Expression patterns of human DAB2IP protein in fetal tissues. Biotechnic & histochemistry : official publication of the Biological Stain Commission 5 22404563
2023 DAB2IP stabilizes p27Kip1 via suppressing PI3K/AKT signaling in clear cell renal cell carcinoma. Functional & integrative genomics 4 37880458
2021 microRNA-1266-5p directly targets DAB2IP to enhance oncogenicity and metastasis in oral cancer. Journal of dental sciences 4 35756756
2018 A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer. Pathology, research and practice 4 30301636
2014 [DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 4 25286682
2024 DAB2IP loss in luminal a breast cancer leads to NF-κB-associated aggressive oncogenic phenotypes. JCI insight 3 39418101
2023 The Tumor Suppressor DAB2IP Is Regulated by Cell Contact and Contributes to YAP/TAZ Inhibition in Confluent Cells. Cancers 3 37444489
2023 circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis. Aging 3 38015711
2018 DAB2IP with tumor-inhibiting activities exhibits frameshift mutations in gastrointestinal cancers. Pathology, research and practice 3 30477644
2016 Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival. Virchows Archiv : an international journal of pathology 3 27003158
2015 Expression of mouse Dab2ip transcript variants and gene methylation during brain development. Gene 2 25958345
2025 Nuclear DAB2IP regulates DNA replication initiation through activating PLK1-mediated HBO1 phosphorylation. Nucleic acids research 1 41261855

Missed literature

Know a paper Affinage missed for DAB2IP? Flag it for the maintainers and the community.

No submissions yet.